CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 600 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07668037
NCT07668037N/ARecruitingOn Track

Characterization of Multi-Omics Landscapes in Long-Term Survival Following Immunotherapy and Development of an AI Pathological Prediction Model for Long-Term Survival Based on H&E-Stained Images in Advanced Non-Small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·observational·Posted Jun 25, 2026·Updated Jun 25, 2026

In Brief

An observational study for Non-Small Cell Carcinoma of Lung and 2 related conditions. Currently recruiting, targeting 600 participants across 1 site.

Detailed Summary

This study is a retrospective, multicenter, observational cohort study in patients with advanced or locally advanced non-small cell lung cancer (NSCLC). The aim of this study was to establish a long-term survival (LTS) versus short-term survival (STS) real-world cohort, to systematically characterize the multi-omics landscapes, and to develop and validate an artificial intelligence (AI) pathological prediction model based on routine H\&E-stained images for predicting immune microenvironment features and long-term survival outcomes following immunotherapy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ARecruiting
2027202820292030
First PostedJun 25, 2026
Enrollment StartMay 1, 2026
Primary CompletionMay 1, 2030
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 6 days agoPrimary completion in 3.8 years

Arms & Interventions

Long-term survival (LTS) groupother

patients with overall survival of more than 5 years after initial immunotherapy

Short-term survival (STS) groupother

patients with overall survival of less than 1 year after initial immunotherapy